Bundamedik Toekomstige groei
Future criteriumcontroles 1/6
Bundamedik is forecast to grow revenue at 10.5% per annum.
Belangrijke informatie
n/a
Groei van de winst
n/a
Groei van de winst per aandeel
| Healthcare winstgroei | 18.8% |
| Inkomstengroei | 10.5% |
| Toekomstig rendement op eigen vermogen | 3.8% |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 01 Nov 2024 |
Recente toekomstige groei-updates
Recent updates
Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 1,932,000 | N/A | N/A | 189,000 | 1 |
| 12/31/2025 | 1,736,000 | N/A | N/A | 170,000 | 1 |
| 12/31/2024 | 1,553,000 | N/A | N/A | 299,000 | 1 |
| 9/30/2024 | 1,546,345 | 13,050 | -223,370 | 61,330 | N/A |
| 6/30/2024 | 1,550,932 | 14,165 | -218,820 | 52,573 | N/A |
| 3/31/2024 | 1,516,514 | 8,378 | -164,487 | 28,889 | N/A |
| 12/31/2023 | 1,488,197 | 7,461 | -157,915 | 51,439 | N/A |
| 9/30/2023 | 1,528,827 | 15,708 | -25,880 | 66,366 | N/A |
| 6/30/2023 | 1,565,526 | 34,028 | 24,224 | 96,722 | N/A |
| 3/31/2023 | 1,655,224 | 64,463 | -46,987 | 134,687 | N/A |
| 12/31/2022 | 1,658,688 | 83,228 | -170,646 | 131,084 | N/A |
| 9/30/2022 | 1,796,504 | 96,161 | -227,176 | 306,568 | N/A |
| 6/30/2022 | 1,803,530 | 133,169 | -254,125 | 298,580 | N/A |
| 3/31/2022 | 1,829,486 | 178,965 | -113,811 | 352,809 | N/A |
| 12/31/2021 | 1,890,800 | 214,489 | 51,263 | 349,438 | N/A |
| 9/30/2021 | 1,657,759 | 214,536 | 100,156 | 199,995 | N/A |
| 6/30/2021 | 1,585,714 | 207,760 | 138,256 | 201,985 | N/A |
| 3/31/2021 | 1,366,053 | 145,128 | 123,810 | 163,858 | N/A |
| 12/31/2020 | 1,148,144 | 88,791 | 140,752 | 190,359 | N/A |
| 12/31/2019 | 964,893 | 19,895 | 17,214 | 89,715 | N/A |
| 12/31/2018 | 852,233 | 5,128 | -41,146 | 115,396 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: Insufficient data to determine if BMHS's forecast earnings growth is above the savings rate (6.8%).
Winst versus markt: Insufficient data to determine if BMHS's earnings are forecast to grow faster than the ID market
Hoge groeiwinsten: Insufficient data to determine if BMHS's earnings are expected to grow significantly over the next 3 years.
Omzet versus markt: BMHS's revenue (10.5% per year) is forecast to grow faster than the ID market (10% per year).
Hoge groei-inkomsten: BMHS's revenue (10.5% per year) is forecast to grow slower than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: BMHS's Return on Equity is forecast to be low in 3 years time (3.8%).